Is the mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis

Hepatology

Volumn 23, Issue 5, 1996, Pages 1148-1153

  Kilmurry, Matthew R ^a   Heathcote, E Jenny ^a,k   Cauch Dudek, Karen ^a   O'Rourke, Keith ^b   Bailey, Robert J ^c   Blendis, Laurence M ^a   Ghent, Cameron N ^d   Minuk, Gerald Y ^e   Chris Pappas, S ^a   Scully, Linda J ^f   Steinbrecher, Urs P ^g   Sutherland, Lloyd R ^h   Noel Williams, C ⁱ   Worobetz, Lawrence J ^j  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c ROYAL ALEXANDRA HOSPITAL   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

^j UNIVERSITY OF SASKATCHEWAN   (Canada)

^k TORONTO WESTERN HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILIARY CIRRHOSIS; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

ADULT; AGED; BILIRUBIN; CANADA; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; MODELS, THEORETICAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; URSODEOXYCHOLIC ACID;

EID: 14644440885     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510230532     Document Type: Article

References (21)

1. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary bilirubin cirrhosis. Gut 1979;20:137-140.
2. Neuberger J, Gunson B, Buckels J, Elias E, McMaster P. Referral of patients with primary bilirubin cirrhosis for liver transplantation. Gut 1990;31:1069-1072.
3. Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portmann B, Doniach D, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology 1985;89:1084-1091.
4. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histological features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983;308:1-7.
5. Bonsel GJ, Klompmaker U, Van 'T Veer F, Habbema JDF, Slooff MJH. Use of prognostic models for assessment of value of liver transplantation in primary biliary cirrhosis. Lancet 1990;335:493-497.
6. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. HEPATOLOGY 1989;10:1-7.
7. Grambsch PM, Dickson RE, Kaplan M, LeSage G, Fleming TR, Langworthy AL. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. HEPATOLOGY 1989;10:846-850.
8. Christenson E, Altman DG, Neuberger J, De Stavola BL, Tygstrup N, Williams R, and the PBC1 and PBC2 trial groups. Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. Gastroenterology 1993;105:1865-1876.
9. Murtaugh PA, Dickson ER, Van Dam GM, Malinchoc M, Grambsch PM, Langworthy AL, Gips CH. Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. HEPATOLOGY 1994;20:126-134.
10. Leuschner U, Fischer H, Kurtz W, Güldütuna S, Hübner K, Hellstern A, Gatzen M, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989;97:1268-1274.
11. Oka H, Toda G, Ikeda Y, Hashimoto N, Hasumora Y, Kamimura, Ohta Y, et al. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol Jpn 1990;25:774-780.
12. Poupon RE, Balkau B, Eschwege E, Poupon R, and the UDCA-PBC Study Group et al. A multicentre controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324:1548-1554.
13. Battezzati PM, Podda M, Bianchi FB, Naccarato R, Surrend C, Pagliaro L, Manenti F, and the Italian Multicenter Group for the Study of UDCA in PBG. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis: preliminary analysis of a double-blind multicenter trial. J Hepatol 1993;17:332-338.
14. Heathcote EJL, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, et al. The Canadian multicentre double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. HEPATOLOGY 1994;19:1149-1156.
15. Poupon RE, Poupon R, Balkau B, and the UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1342-1347.
16. Lindor KD, Dickson ER, Baldus WP, Jorgenson RA, Ludwig J, Murtaugh PA, Harrison JM, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-1290.
17. Combes B, Carithers RL, Maddrey WC, Munoz SJ, McDonald MF, Garcia-Tsao G, Boyer JL, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis. HEPATOLOGY 1993;18:457-481.
18. Turner IB, Myszor M, Mitchison HC, Bennett MK, Burt AD, James OFW. A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 1994;9:162-168.
19. Heathcote EJ, Lindor KD, Poupon R, Cauch-Dudek K, Dickson ER, Trout R, Poupon RE. Combined analysis of French, American and Canadian randomized controlled trials of ursodeoxycholic acid therapy in primary biliary cirrhosis [Abstract]. Gastroenterology 1995;108:1082.
20. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
21. Poupon RE, Balkau B, Guechot J, Heintzman F. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue. HEPATOLOGY 1994;19:635-640.